Johnson and Johnson

JNJ's Fundamental analysis

Select the Comparisons :

None ▼

Select the Ratio:

None▼

None ▼

None▼

JNJ Growth rates comparisons

Looking into Johnson And Johnson growth rates, revenue grew by 6.77 % in the third quarter of 2025 from the same quarter a year ago. Ranking at No. 108

Major Pharmaceutical Preparations industry recorded growth of revenues by 10.26 %

Johnson And Johnson's net income grew by 91.24 % in third quarter of 2025 year on year, above company average,

• More on JNJ's Growth

JNJ's Valuation comparisons

Johnson And Johnson
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Johnson And Johnson PEG ratio is at 0.25 Johnson And Johnson realized cash reduction of $ -0.72 per share in trailing twelve-month period.

Company

PE TTM

Industry

PE TTM

Company's Price to Sales ratio is at 4.92.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.87.

• More on JNJ's Valuation

Total Debt (Millions $)	45,795
Dividend TTM ($)	5.04 $
Dividend Yield TTM (%)	2.76 %
Revenue/Employee (TTM) $	685,632
Net Income/Employee (TTM) $	186,897
Receivable Turnover (TTM)	5.56
Tangible Book Value (Per Share $)	-7.21

JNJ's Valuation comparisons

Johnson And Johnson
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Johnson And Johnson PEG ratio is at 0.25 Johnson And Johnson realized cash outflow of $ -0.72per share in trailing twelve-month period.

Company

PE TTM

Industry

PE TTM

Company's Price to Sales ratio is at 4.92.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.87.

Johnson And Johnson Price to Book Ratio is at 5.72 lower than Industry Avg. of 39.17. and higher than S&P 500 Avg. of 0.02

• More on JNJ's Valuation

• Market Capitalization (Millions $)	453,449
• Shares Outstanding (Millions)	2,429
• Employees	134,400
• Revenues (TTM) (Millions $)	92,149
• Net Income (TTM) (Millions $)	25,119
• Cash Flow (TTM) (Millions $)	-1,749
• Capital Exp. (TTM) (Millions $)	-4,607
• Total Debt (Millions $)	45,795
• Dividend TTM ($)	5.04 $
• Dividend Yield TTM (%)	2.76 %
• Revenue/Employee (TTM) $	685,632
• Net Income/Employee(TTM) $	186,897
• Receivable Turnover Ratio (TTM)	5.56
• Tangible Book Value (Per Share $)	-7.21

• Market Capitalization (Millions $)	453,449
• Shares Outstanding (Millions)	2,429
• Employees	134,400
• Revenues (TTM) (Millions $)	92,149
• Net Income (TTM) (Millions $)	25,119
• Cash Flow (TTM) (Millions $)	-1,749
• Capital Exp. (TTM) (Millions $)	-4,607

JNJ's Profitability Comparisons

Johnson And Johnson achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in third quarter of 2025 to 29.31 % from 27.99 % in II. Quarter.

Johnson And Johnson net profit margin of 21.47 % is currently ranking no. 9 in Major Pharmaceutical Preparations industry, ranking no. 22 in Healthcare sector and number 268 in S&P 500.

Profitability by Segment
Total	21.47 %

	*Ratio*
• Capital Ratio (MRQ)	1.85
• Total Debt to Equity (MRQ)	0.58
• Tangible Leverage Ratio (MRQ)	-
• Asset Turnover Ratio (TTM)	0.51
• Inventory Turnover Ratio (TTM)	2.23

JNJ's Profitability Comparisons

Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.